Meeting
2023 ASCO Annual Meeting
Tracking the evolving ecosystem of recurrent hepatocellular carcinoma after liver transplantation.
Authors
Zijie Zhang
Renji Hospital, affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Zijie Zhang , Gaoyang Wang , Youqiong Ye , Hao Feng , Qiang Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04506398
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4114)
DOI
10.1200/JCO.2023.41.16_suppl.4114
Abstract #
4114
Poster Bd #
435
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer.
First Author: De-Zhen Guo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation.
First Author: Mehmet Akce
Poster
2023 ASCO Annual Meeting
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.
First Author: David A. Braun
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
First Author: Davendra Sohal